Kineret Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to unmet needs in inflammatory disorders, clinical success of il 1 blockade, improved diagnosis of rare syndromes, hospital adoption of biologics, long term safety data availability.

The growth in the forecast period can be attributed to growing recognition of autoinflammatory diseases, expansion into new indications, increasing pediatric biologic use, improved access to specialty care, ongoing biologic innovation. Major trends in the forecast period include expansion of il 1 inhibitor use, rising treatment of autoinflammatory diseases, growth in pediatric inflammatory care, preference for targeted cytokine therapies, increased use in rare inflammatory syndromes.

The rising prevalence of autoimmune diseases is expected to significantly drive the growth of the Kineret market in the future. Autoimmune diseases refer to a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs, treating them as foreign invaders. The increasing prevalence of autoimmune diseases is influenced by a combination of genetic, environmental, and lifestyle factors. Kineret is a medication that can be effective in treating autoimmune diseases, particularly in managing conditions characterized by excessive inflammation caused by the immune system attacking the body's tissues. For example, in May 2023, the National Institute for Health and Care Research (NIHR), a UK-based health and care research organization, reported a study involving 22 million people, revealing that autoimmune disorders now affect approximately one in ten individuals. The study found that 19 autoimmune diseases impact about 10% of the population, with 13% of women and 7% of men being affected. As a result, the growing prevalence of autoimmune diseases is contributing to the growth of the Kineret market.

The increasing prevalence of inflammatory diseases is expected to further propel the growth of the Kineret market. Inflammatory diseases refer to a group of conditions in which the immune system abnormally responds, causing chronic or acute inflammation in tissues or organs. The rising prevalence of these diseases is driven by several factors, including an aging population, greater exposure to environmental pollution, and lifestyle factors such as poor diet, sedentary habits, and smoking. Kineret (anakinra) helps manage inflammatory diseases by inhibiting interleukin-1 (IL-1), a key protein that drives the inflammatory response. For instance, in 2023, Crohn's and Colitis Canada, a non-profit organization, reported that the number of people in Canada with inflammatory bowel disease (IBD) is rising rapidly, from 322,600 in 2023 (0.8% of the population) to 470,000 by 2035 (1.1% of the population). In 2023, 11,000 new diagnoses were made (approximately 1 every 48 minutes), and this number is expected to increase to 14,000 by 2035 (1 every 38 minutes). Consequently, the rising prevalence of inflammatory diseases is driving the growth of the Kineret market.

A key trend in the Kineret market is the adoption of strategic partnerships to develop innovative Kineret-based products and gain a competitive edge. These collaborations allow companies in the Kineret market to pool resources and expertise, enhance research and development efforts, expand market reach, and accelerate product commercialization, driving innovation and growth in the industry. For example, in May 2024, Swedish Orphan Biovitrum AB (Sobi), a Sweden-based biopharmaceutical company, partnered with Handok Inc., a South Korea-based pharmaceutical company, to launch Kineret (anakinra) in South Korea. This partnership combines Handok’s local expertise with Sobi’s global capabilities, particularly in the field of rare diseases.

Major companies operating in the kineret market are Sobi (Swedish Orphan Biovitrum AB)

North America was the largest region in the kineret market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kineret market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the kineret market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have impacted the kineret market by increasing costs associated with recombinant protein production and injectable delivery systems. Hospital pharmacies and specialty clinics in europe and north america are most affected due to biologic import dependence. These tariffs may influence treatment accessibility in rare diseases. At the same time, tariffs are encouraging domestic biologics manufacturing and strengthening regional supply chains for inflammatory therapies.

The kineret market research report is one of a series of new reports that provides kineret market statistics, including kineret industry global market size, regional shares, competitors with a kineret market share, detailed kineret market segments, market trends and opportunities, and any further data you may need to thrive in the kineret industry. This kineret market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Kineret is the brand name for anakinra, a prescription medication primarily used to treat specific inflammatory conditions. It is a recombinant form of the human interleukin-1 receptor antagonist (IL-1Ra), which works by inhibiting the activity of interleukin-1 (IL-1), a protein involved in inflammatory and immune responses.

The main indications for Kineret include the treatment of rheumatoid arthritis, Still's disease, cryopyrin-associated periodic syndromes, and neonatal-onset multisystem inflammatory disease (NOMID). Rheumatoid arthritis is an autoimmune condition that causes chronic inflammation, pain, and swelling in the joints, potentially leading to joint damage and disability. Kineret is available in injectable formulations (subcutaneous) and pre-filled syringes or auto-injectors. It is used by various patient demographics, including pediatric, adult, and geriatric patients. The medication is distributed through hospital pharmacies, retail pharmacies, online pharmacies, and wholesalers, and it is used by a range of healthcare providers, such as hospitals, specialty clinics, outpatient treatment centers, and home healthcare providers.

The kineret market consists of sales of pre-filled syringes and auto-injectors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.